Gleason Score News and Research

RSS

Higher doses of radiation do not translate into longer survival for prostate cancer patients

A new study shows that higher doses of radiation do not improve survival for many patients with prostate cancer, compared with the standard radiation treatment.

15 Mar 2018

Multimodal treatment approach enhances long-term survival in men with metastatic prostate cancer

UCLA researchers have discovered that a combination of high doses of radiotherapy and hormonal therapy provides the best chance of decreasing the mortality rate in men with aggressive prostate cancer.

5 Mar 2018

Obese men may have elevated risk of biochemical recurrence after radical prostatectomy

Among men with prostate cancer who underwent radical prostatectomy (RP), those who were obese had a higher risk of biochemical recurrence, according to data presented at the American Association for Cancer Research Special Conference Obesity and Cancer: Mechanisms Underlying Etiology and Outcomes, held Jan. 27-30.

27 Jan 2018

Men who follow Mediterranean diet have lower risk of aggressive prostate cancer, study finds

In a new study published in The Journal of Urology, researchers determined that men who followed a Mediterranean diet, rich in fish, boiled potatoes, whole fruits, vegetables, legumes, and olive oil, and low consumption of juices had lower risk of aggressive prostate cancer than those who followed other dietary patterns like Prudent or Western diets.

10 Jan 2018

PET scans can predict prostate cancer patients’ response to salvage radiation treatment

For prostate cancer patients who have rising levels of PSA (a cancer indicator) even after radical prostatectomy, early treatment makes a difference.

5 Dec 2017

New CSHL method pinpoints which prostate tumors pose fatal threat before surgery

The facts about prostate cancer can be confusing. It's the third most common cancer type among Americans - 161,000 men will be diagnosed this year, the National Cancer Institute estimates. Yet according to the NCI, 98.6% will be alive in 5 years.

1 Dec 2017

Common genetic fusion event could help identify patients with low-risk prostate cancer

Establishing the way in which a genetic alteration called a TMPRSS2-ERG gene fusion forms in a prostate cancer, rather than the presence of the gene fusion itself, could help identify patients with prostate cancer with a low risk of spreading, which might determine the best course of treatment for the patient.

10 Nov 2017

Prostate Cancer Awareness Month: Myriad Genetics working to educate public about hereditary cancer risk assessment

Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, is working to educate the public about hereditary cancer risk assessment and testing during Prostate Cancer Awareness Month this September.

11 Sep 2017

Prostate cancer screening reduces cancer deaths finds new analysis

There has been much debate regarding the utility of prostate cancer screening in reducing the rates of deaths due to this cancer among men. While the ERSPC (European Randomized Study of Screening for Prostate Cancer) suggests that screening reduced prostate cancer deaths, the PLCO (Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial) found that regular screening does not reduce the cancer death rates in prostate cancer. Researchers thus looked at the actual picture as to which of these – ERSPC or PLCO are correct.

5 Sep 2017

Surgery may not prolong life in men with early-stage prostate cancer

A major 20-year study provides further evidence that prostate cancer surgery offers negligible benefits to many men with early-stage disease.

13 Jul 2017

Prolaris becomes first genetic test to receive Medicare coverage for favorable intermediate and low-risk prostate cancer

Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced that Palmetto GBA, a Medicare Administrative Contractor that assesses molecular diagnostic technologies, has issued a positive final Local Coverage Determination to expand Medicare coverage of the Prolaris test.

29 May 2017

Protein testing may become potential tool to detect prostate cancer

In 2016, more than 181,000 new cases of prostate cancer were reported in the U.S., according to the American Cancer Society. The prostate-specific antigen (PSA) test is one of the earliest ways clinicians can detect prostate cancers in their patients.

5 Apr 2017

New genetic test may give men better view on how to deal with prostate cancer risk

Scientists are reporting a test which can predict which patients are most at risk from aggressive prostate cancer, and whether they suffer an increased chance of treatment failure.

27 Mar 2017

Research finds disparity in rates of prostate cancer treatment among African-American, Hispanic men

African-American and Hispanic men in the United States are less likely to receive therapy for prostate cancer compared to Caucasian men — even when they have more aggressive disease, according to new research from Roswell Park Cancer Institute and Vanderbilt University Medical Center.

7 Oct 2016

Intermediate risk prostate cancer patients can achieve survival benefit with brachytherapy alone

For men with intermediate risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects, when compared to more aggressive treatment that combines brachytherapy with external beam therapy (EBT), according to research presented today at the 58th Annual Meeting the American Society for Radiation Oncology.

27 Sep 2016

Management of prostate cancer varies by race

A study published in The Journal of Urology® indicates that treatment for low-risk prostate cancer, rather than watchful waiting, is most likely to be sought by black men.

29 Jul 2016

Active surveillance improves health related quality of life in low risk prostate cancer patients

Active surveillance (AS) has become an increasingly important alternative to surgery, chemotherapy, or radiation treatment for men diagnosed with low risk prostate cancer.

25 Jul 2016

Changes in benign tissue adjacent to prostate tumors could better predict recurrence

Changes in benign tissues next to prostate tumors may provide an early warning for patients at higher risk for biochemical recurrence after a radical prostatectomy, a study by researchers at Case Western Reserve University and Johns Hopkins Medical Institutions shows.

6 Jul 2016

Study assesses risk factors for metastases in prostate cancer patients on active surveillance

Radical treatment such as surgery and radiation for localized prostate cancer may cause significant side effects. Active surveillance is increasingly accepted as an option for treating patients with clinically insignificant disease to maintain their quality of life.

12 Apr 2016

Experimental urine test identifies 92% of men with elevated PSA levels

An experimental urine test that detects genetic changes associated with prostate cancer identified 92 percent of men with elevated PSA (prostate-specific antigen) levels who had high-grade cancers, according to a study published today in JAMA Oncology online.

1 Apr 2016